Biopharmaceutical Research Company, a Monterey, CA-based holder of an active Drug Enforcement Administration (DEA) pharmaceutical cannabis license, raised $20M in Series A funding.
The round was led by Intrinsic Capital Partners, with participation from Argonautic Ventures, Achari Ventures, AFI Capital Partners, Delta Emerald Ventures, and Self Health America, and a number of preeminent family offices.
The company intends to use the funds to scale up and increase product offering, conduct sponsored research, and execute on its go-to-market strategy.
Led by CEO George Hodgin, Biopharmaceutical Research Company (BRC) is a DEA-registered botanical cannabis firm focused on the federally compliant production of active pharmaceutical ingredients and partnered development and research.
In recent years, BRC has partnered with academic research institutions including Washington State Universityand the University of California-Davis.
FinSMEs
04/10/2022